#United States #RNA Sequencing #Morrisville #CS Genetics #Carolina Molecular

Carolina Molecular Partners with CS Genetics

In a notable advancement for the field of genomics, Carolina Molecular, a respected clinical sequencing laboratory, has officially been designated as a Certified Service Provider (CSP) for CS Genetics. This collaboration aims to make single-cell RNA sequencing (scRNA-Seq) more accessible and cost-effective, paving the way for major innovations in translational and clinical research.

Enhancing Research Capabilities

With a growing interest in scRNA-Seq among researchers focusing on areas such as neurobiology, cancer, and immunology, Carolina Molecular’s President, Trent Carrier, expressed enthusiasm about this new alliance. According to Carrier, there's a noticeable shift towards seeking improved methods for generating and analyzing data that sheds light on cellular behaviors and biological developments. The capabilities of the CS Genetics platform, known for its speed, scalability, and affordability, resonate with the needs of Carolina Molecular's users.

Founded in 2014 in Cambridge, UK, CS Genetics has been at the forefront of overcoming the limitations of existing scRNA-Seq methodologies with its SimpleCell™ platform. This innovative technology is designed to generate libraries ready for sequencing from individual cells in less than a day and at an economically viable price—an essential feature for varied experimental sizes. The SimpleCell platform supports a diverse array of sample types, including PBMCs, cell lines, and even disaggregated tissues, integrating well with popular bioinformatics pipelines and analysis tools used widely in research like Python and R.

Efficient and Cost-Effective Solutions

Dr. Bill Colston, CEO of CS Genetics, highlighted the synergy between Carolina Molecular’s expertise in sequencing and bioinformatics with the capabilities of their technology. He noted that researchers are often frustrated by the steep costs associated with conducting meaningful single-cell studies, prompting a desire for more substantial and insightful experimental outcomes. The partnership intends to enable these researchers to devise larger, more impactful studies that enhance understanding of cellular diversity in various diseases.

As they move forward, Carolina Molecular and CS Genetics are in active discussions with potential collaborators in promising research arenas. Moreover, they are focused on gathering samples and developing data that will be made publicly available in the upcoming months, further benefiting the research community.

Carrier underscored the existing substantial overlap in clientele between the two organizations. With the launch of this collaboration, he anticipates a significant uptake of CS Genetics’s offerings as promotional efforts commence.

About Carolina Molecular

With over 20 years of experience, Carolina Molecular stands out as a leading laboratory in molecular testing. They provide CAP/CLIA-certified and New York State-registered testing services tailored for CROs and clinical trial sponsors. With their NGS Foundry, they offer project-based sequencing options and quality control testing that comply with the highest regulatory standards, ensuring reliable service delivery across diverse research projects.

About CS Genetics

CS Genetics is a privately-held genomics technology company located in San Diego, California. Their groundbreaking instrument-free platform for single-cell genomics not only simplifies the sequencing process but also enhances scalability, potentially initiating a new chapter in NGS-based cellular analysis. Their innovative technology, which utilizes Kinetic Confinement, is distinctly different from existing single-cell solutions and easily integrates into standard laboratory setups. CS Genetics boasts a vast global intellectual property portfolio covering its single-cell platform alongside associated reagents and technologies.

As both companies dive deeper into this partnership, the impact on the landscape of genomics research is poised to be significant, benefiting scientists looking to amplify their findings while minimizing costs.